Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: A Meta-Analysis of Original Data From 7 Randomized Controlled Trials
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
BACKGROUND: Although it is widely believed that the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes a meta-analysis of original data from a complete set of studies comparing the norepinephrine/dopamine reuptake inhibitor (NDRI) bupropion with selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, or paroxetine). METHOD: Individual patient data were pooled from a complete set of 7 randomized, double-blind studies comparing bupropion (N = 732) with SSRIs (fluoxetine, N = 339; sertraline, N = 343; paroxetine, N = 49) in outpatients with major depressive disorder (DSM-III-R or DSM-IV); 4 studies included placebo (N = 512). Response and remission rates were compared at week 8 or endpoint in both the intent-to-treat sample, using the last-observation-carried-forward (LOCF) method to account for attrition, and the observed cases. Tolerability data, including incidence of sexual side effects, were also compared. RESULTS: The LOCF response and remission rates for the bupropion (62% and 47%) and SSRI (63% and 47%) groups were similar; both active therapies were superior to placebo (51% and 36%; all comparisons, p < .001). The same pattern of results was demonstrated on the observed cases analyses. Although bupropion and SSRIs were generally well tolerated, SSRI therapy resulted in significantly higher rates of sexual side effects as compared to both bupropion and placebo. SSRIs were also associated with more somnolence and diarrhea, and bupropion was associated with more dry mouth. CONCLUSION: Bupropion and the SSRIs were equivalently effective and, overall, both treatments were well tolerated. The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, SSRIs and other traditional antidepressants are problematic as they typically take weeks before therapeutic effects are observed and require daily administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Thase et al., 2005
In the citing paper
“Particularly relevant in the present context are previous reports [290,296,297] that although both DA and non-DA agents can be used to effectively treat mood disorders, DA agents generally have superior effects on symptoms of anhedonia, specifically when compared with non-DA agents [19,298-300].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
In the citing paper
“Bupropion, a DA and norepinephrine reuptake inhibitor, is an effective antidepressant [290] that seems to specifically increase feelings of positive affect [291].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
Citations
Cites
Still being checked.
Cited by
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript et al., 1997; Mendels et al., 1983; Thase et al., 2005; Weihs et al., 2000; Weisler et al., 1994).”
BackgroundPRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Self-citationAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Laje, G., Fava, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 474
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Self-citationNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Papakostas, G. I., Nutt, D. J., Hallett, L. A., Tucker, V. L., Krishen, A., & Fava, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.015 · Cited by 334
Synaptic plasticity in depression: Molecular, cellular and functional correlates
Marsden, W. N. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.012 · Cited by 317
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“Meta-analyses for sertraline or paroxetine, however, did not find any superiority to each other or to escitalopram on efficacy (Thase et al., 2005; Cipriani et al., 2010).”
BackgroundLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Ketamine and the next generation of antidepressants with a rapid onset of action
Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.010 · Cited by 276
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258
Self-citationSchmaal, L., Pozzi, E., C. Ho, T., van Velzen, L. S., Veer, I. M., Opel, N., Van Someren, E. J. W., Han, L. K. M., Aftanas, L., Aleman, A., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0842-6 · Cited by 245
Maeng, S., & Zarate, C. A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0063-1 · Cited by 229
A Review of Treating Depression in Diabetes: Emerging Findings
Markowitz, S. M., Gonzalez, J. S., Wilkinson, J. L., & Safren, S. A. (2011) · Psychosomatics · doi:10.1016/j.psym.2010.11.007 · Cited by 230
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224
Hu, X.-Z., Rush, A. J., Charney, D., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Fava, M., Trivedi, M. H., Wisniewski, S. R., Laje, G., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.783 · Cited by 218
Strategies to Improve the Management of Depression in Primary Care
Unützer, J., & Park, M. (2012) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2012.03.010 · Cited by 197
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
Dimensional personality traits and treatment outcome in patients with major depressive disorder
Quilty, L. C., De Fruyt, F., Rolland, J.-P., Kennedy, S. H., Rouillon, P. F., & Bagby, R. M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.022 · Cited by 177
Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?
Clayton, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.457 · Cited by 186
Bagby, R. M., Quilty, L. C., Segal, Z. V., McBride, C. C., Kennedy, S. H., & Costa, P. T. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300605 · Cited by 172
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
Antidepressants and sexual dysfunction
Werneke, U., Northey, S., & Bhugra, D. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00890.x · Cited by 176
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Dopaminergic-based pharmacotherapies for depression
Papakostas, G. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.002 · Cited by 168
SSRI-Associated Sexual Dysfunction
Balon, R. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1504 · Cited by 166
Ji, Y., Hebbring, S., Zhu, H., Jenkins, G. D., Biernacka, J., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.250 · Cited by 160
Toward achieving optimal response: understanding and managing antidepressant side effects
Kelly, K., Posternak, M., & Jonathan, E. A. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/kkelly · Cited by 150
Physical Exercise and Neuroinflammation in Major Depressive Disorder
Ignácio, Z. M., da Silva, R. S., Plissari, M. E., Quevedo, J., & Réus, G. Z. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01670-1 · Cited by 153
CYP2C19 variation and citalopram response
Mrazek, D. A., Biernacka, J. M., O'Kane, D. J., Black, J. L., Cunningham, J. M., Drews, M. S., Snyder, K. A., Stevens, S. R., Rush, A. J., & Weinshilboum, R. M. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328340bc5a · Cited by 148
Krogh, J., Saltin, B., Gluud, C., & Nordentoft, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04241 · Cited by 147
Singh, A. B. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.2.150 · Cited by 142
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138
Bupropion: A Review of its Use in the Management of Major Depressive Disorder
Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008) · Drugs · doi:10.2165/00003495-200868050-00011 · Cited by 156
SLC6A4 variation and citalopram response
Mrazek, D. A., Rush, A. J., Biernacka, J. M., O'Kane, D. J., Cunningham, J. M., Wieben, E. D., Schaid, D. J., Drews, M. S., Courson, V. L., Snyder, K. A., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30816 · Cited by 136
Insomnia and depression: a multifaceted interplay
Manber, R., & Chambers, A. S. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0066-1 · Cited by 134
“Somnolence is less frequently reported as a side effect of bupropion [ 43 ] and reboxetine [47] and more frequently reported with use of mirtazapine and trazodone [45].”
BackgroundResultInfluentialSexual Side-Effects of Contemporary Antidepressants: Review
Schweitzer, I., Maguire, K., & Ng, C. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903107575 · Cited by 128
Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?
Argyropoulos, S. V., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494104 · Cited by 126
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Advances in the treatment of depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.007 · Cited by 141
Möller, H.-J. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970801981606 · Cited by 114
Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach
Montejo, A. L., Prieto, N., de Alarcón, R., Casado‐Espada, N. M., de la Iglesia, J., & Montejo, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101640 · Cited by 121
Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
Zhao, J., Verwer, R. W. H., Gao, S.-F., Qi, X.-R., Lucassen, P. J., Kessels, H. W., & Swaab, D. F. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.04.020 · Cited by 102
Uebelacker, L. A., Tremont, G., Epstein-Lubow, G., Gaudiano, B. A., Gillette, T., Kalibatseva, Z., & Miller, I. W. (2010) · Behavior Modification · doi:10.1177/0145445510368845 · Cited by 89
The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects
Dell’Osso, B., Palazzo, M. C., Oldani, L., & Altamura, A. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00217.x · Cited by 96
Emerging drugs for major depressive disorder
Connolly, K. R., & Thase, M. E. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.660146 · Cited by 96
Self-citationClarke, M., Razmjou, S., Prowse, N. A., Dwyer, Z., Litteljohn, D., Pentz, R., Anisman, H., & Hayley, S. P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.021 · Cited by 97
Thase, M. E., Clayton, A. H., Haight, B. R., Thompson, A. H., Modell, J. G., & Johnston, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239790.83707.ab · Cited by 90
Self-citationNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Chang, M., Tybring, G., Dahl, M., & Lindh, J. D. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0162-1 · Cited by 91
A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy
Gilliam, F. G., BLACK, K. J., Carter, J., Freedland, K. E., Sheline, Y. I., Tsai, W., & Lustman, P. J. (2019) · Annals of Neurology · doi:10.1002/ana.25561 · Cited by 95
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Self-citationA Placebo-Controlled Trial of Bupropion SR in the Treatment of Chronic Posttraumatic Stress Disorder
Becker, M. E., Hertzberg, M. A., Moore, S. D., Dennis, M. F., Bukenya, D. S., & Beckham, J. C. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318032eaed · Cited by 84
Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review - Part I: Antidepressants
La Torre, A., Giupponi, G., Duffy, D., & Conca, A. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1345205 · Cited by 82
Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M., & Ning, Y. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.09.007 · Cited by 86
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 91
Pharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationCooper, J. A., Tucker, V. L., & Papakostas, G. I. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113514878 · Cited by 76
Bortnick, B., El-Khalili, N., Banov, M. D., Adson, D. E., Datto, C. J., Raines, S. R., Earley, W. R., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.031 · Cited by 93
Ji, Y., Biernacka, J. M., Hebbring, S., Chai, Y., Jenkins, G. D., Batzler, A., Snyder, K. A., Drews, M. S., Desta, Z., Flockhart, D., et al. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.32 · Cited by 76
Grunebaum, M. F., Ellis, S. P., Duan, N., Burke, A. K., Oquendo, M. A., & John Mann, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.247 · Cited by 79
Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1001 · Cited by 79
Self-citationPapakostas, G. I., Trivedi, M. H., Alpert, J. E., Seifert, C. A., Krishen, A., Goodale, E. P., & Tucker, V. L. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.012 · Cited by 82
Sexual Dysfunction Due to Psychotropic Medications
Clayton, A. H., Alkis, A. R., Parikh, N., & Votta, J. G. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.006 · Cited by 86
A Review of Modern Antidepressants Effects on Neurocognitive Function
Biringer, E., Rongve, A., & Lund, A. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009788971137 · Cited by 73
“Since it was launched in 1989, bupropion has proven to be an effective and well-tolerated antidepressant [108, 109].”
BackgroundRobinson, R. L., Long, S. R., Chang, S., Able, S., Baser, O., Obenchain, R., & Swindle, R. W. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.1.43 · Cited by 69
Bousman, C., Jaksa, P., & Pantelis, C. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000303 · Cited by 71
Ketamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 72
First‑line pharmacotherapies for depression – what is the best choice?
Koenig, A. M., & Thase, M. E. (2009) · Polish Archives of Internal Medicine · doi:10.20452/pamw.743 · Cited by 67
Self-citationManaging the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
The role of pharmacogenetics in the treatment of depression and anxiety disorders
Schosser, A., & Kasper, S. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283306a2f · Cited by 69
Schwasinger-Schmidt, T. E., & Macaluso, M. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_167 · Cited by 74
Jha, M. K., Wakhlu, S., Dronamraju, N., Minhajuddin, A., Greer, T. L., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.089 · Cited by 60
Zhou, Z., Zhang, G., Li, X., Liu, X., Wang, N., Qiu, L., Liu, W., Zuo, Z., & Yang, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8798-2 · Cited by 64
Marsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 72
van der Lem, R., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330890 · Cited by 63
Ellsworth, K. A., Moon, I., Eckloff, B. W., Fridley, B. L., Jenkins, G. D., Batzler, A., Biernacka, J. M., Abo, R., Brisbin, A., Ji, Y., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dc133 · Cited by 60
Szymkowicz, S. M., Finnegan, N., & Dale, R. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.015 · Cited by 61
Katzelnick, D. J., Duffy, F. F., Chung, H., Regier, D. A., Rae, D. S., & Trivedi, M. H. (2011) · Psychiatric Services · doi:10.1176/ps.62.8.pss6208_0929 · Cited by 56
Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089602 · Cited by 57
Self-citationGuo, M., & Lu, X.-Y. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.126 · Cited by 55
Shwartz, A., Betzer, O., Kronfeld, N., Kazimirsky, G., Cazacu, S., Finniss, S., Lee, H. K., Motiei, M., Dagan, S. Y., Popovtzer, R., et al. (2017) · Theranostics · doi:10.7150/thno.18914 · Cited by 59
Hewett, K., Chrzanowski, W., Jokinen, R., Felgentreff, R., Shrivastava, R., Gee, M., Wightman, D., O'Leary, M., Millen, L., Leon, M., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108100254 · Cited by 54
Self-citationEstrogens of multiple classes and their role in mental health disease mechanisms
Watson, C. (2010) · International Journal of Women's Health · doi:10.2147/ijwh.s6907 · Cited by 50
Taylor, J. E., Yamada, T., Kawashima, T., Kobayashi, Y., Yoshihara, Y., Miyata, J., Murai, T., Kawato, M., & Motegi, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-05860-1 · Cited by 62
The effects of agomelatine on sexual function in depressed patients and healthy volunteers
Montejo, A., Majadas, S., Rizvi, S. J., & Kennedy, S. H. (2011) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1243 · Cited by 51
Antidepressant-related sexual dysfunction — Perspectives from neuroimaging
Graf, H., Walter, M., Metzger, C. D., & Abler, B. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.12.003 · Cited by 55
Baghai, T. C., Volz, H., & Möller, H. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601003973 · Cited by 59
Metadata
- Authors
- Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y.
- Affiliations
- University of Pittsburgh Medical Center (US)
- GlaxoSmithKline (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-08-15
- Volume
- 66
- Issue
- 08
- Pages
- 974-981
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089694151
- Cited by
- 304
- References
- 0
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 15 · 2016: 18 · 2015: 10 · 2014: 20 · 2013: 18 · 2012: 23
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- bupropion, selective serotonin reuptake inhibitors, major depressive disorder, antidepressant efficacy, remission rate, sexual dysfunction, drug tolerability, fluoxetine, sertraline, paroxetine, norepinephrine-dopamine reuptake inhibitors, placebo comparison
- MeSH terms
- Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Bupropion, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.